ReviewTranslational gastroenterology and hepatology2025
Comparison between fecal calprotectin and magnetic resonance enterography in ileal Crohn's disease for activity disease assessment: a systematic review.
Review in Translational gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification and validation of fecal complement component 3 and fibronectin as potential biomarkers for monitoring disease activity in ulcerative colitis based on a mouse model.Animal models and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Crohn's disease (CD) is a chronic inflammatory condition requiring regular follow-up through consultations and monitoring via laboratory, radiographic, and endoscopic examinations. Fecal calprotectin (FC) and magnetic resonance (MR) enterography are prominent non-invasive methods for assessing disease activity. However, while MR enterography is a valuable diagnostic tool, its high cost and limited accessibility present challenges for widespread use. In contrast, FC is a more affordable and accessible biomarker. To perform a systematic review (SR) examining the correlation between FC levels and MR enterography findings in patients with ileal CD. Methods: A systematic literature search was conducted across the following databases: PubMed, PubMed PMC, BVS-BIREME, SCOPUS, Web of Science, EMBASE, and Cochrane Library, and it was completed in October 2024. Results: Eight studies were included in this SR. Seven demonstrated a positive correlation between FC levels and MR enterography findings. Additionally, two studies reported significantly lower FC levels in ileal CD than in exclusive colonic or ileocolonic CD cases. The FC cutoff values ranged from >100 to >430 µg/g of feces to determine the activity of the disease. Conclusions: FC proved to be a reliable biomarker for diagnosing and monitoring CD, demonstrating a positive correlation with findings from MR enterography.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.